Can treatment of unexplained recurrent abortion patients with nitric oxide donors decrease the incidence of abortion?

Comparative study between folic acid control group and folic acid plus isosorbid mononitrate as a nitric oxide donors study group treatment of unexplained recurrent abortion patients as regards incidence of abortion

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000808640

Enrollment

Registered

2014-07-30

Start date

2013-01-01

Completion date

2013-12-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study included a control and a study group each 30 cases with history of unexplained recurrent abortion. The control group was treated with folic acid tablet 0.5 mg once daily orally and the study group treated with folic acid plus isosorbid mononitrate 20 mg given vaginally. Treatment was given monthly from day 21-23 of the cycle until menstruation and continued if pregnancy occurred until 20 weeks gestation. Doppler ultrasound was done vaginally before treatment and abdominally at 20 weeks gestation to measure uterine artery resistance and pulsation indices. Patients were treated until 20 weeks gestation to compare uterine artery indices before and after treatment and the incidence of abortion in both groups

Interventions

A control of 30 patients with unexplained recurrent abortion treated with folic acid 0.5 mg once daily orally starting before pregnancy until 20 weeks gestation and a study group of 30 patients treated with folic acid 0.5 mg once daily orally plus isosorbid mononitrate 20 mg dailly applied vaginally

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

20 Years to 30 Years

Healthy volunteers

Inclusion criteria

Patients with unexplained recurrent abortion with normal uterine cavity, normal glucose tolerance, normal levels of antiphospholipid antibodies, normal thyroid functions and normal karyotyping

Exclusion criteria

Patients treated with vasodilators

Outcome results